The next PARP M&A deal? Tesaro shares surge on lat­est buzz about a buy­out

The PARP wars may be about ready to in­spire some fresh M&A ac­tiv­i­ty.

In the wake of Pfiz­er’s big $14 bil­lion ac­qui­si­tion of Medi­va­tion last fall, which in­clud­ed the PARP drug ta­la­zoparib, sources are telling Reuters that Tesaro $TSRO has been field­ing some in­com­ing queries about a buy­out. And with its PARP drug ni­ra­parib un­der re­view at the FDA, Tesaro has be­come one of the most fre­quent­ly cit­ed takeover tar­gets in biotech, where promis­ing late-stage as­sets can be hard to find.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.